Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab plus chemotherapy with or without additional novel agents in resectable NSCLC (perioperative platform study)
2023-509806-31-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised trial of cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Major pathologic response (MPR) rate. Planned start Oct 2024; status: authorised.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509806-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509806-31-00.